CYP51-IN-26 is a CYP51 inhibitor with an IC50 value of approximately 0.40 μM. It effectively eradicates Candida auris biofilms and significantly enhances cellular uptake in accumulation studies. Moreover, CYP51-IN-26 provides protection against Candida auris infection in both G. mellonella and D. melanogaster models. It is applicable for research on fungal infections.

CYP51-IN-26 (Compound 7) accumulates in Candida auris strain TDG1912 at significantly higher levels than Fluconazole. It exhibits antifungal activity against various strains: C. albicans NCNCPF3281 (0.125 μg/mL), N. glabratus NCPF8018 (0.25 μg/mL), C. tropicalis NCPF8760 (0.25 μg/mL), C. parapsilosis NCPF3209 (0.125 μg/mL), TDG1912 (0.25 μg/mL), TDG2512 (0.06 μg/mL), TDG1102 (4 μg/mL), TDG2211 (0.5 μg/mL), TDG2506 (≤ 0.03 μg/mL), NCPF8984 (≤ 0.03 μg/mL), NCPF8971 (≤ 0.25 μg/mL), and NCPF8977 (≤ 0.03 μg/mL). CYP51-IN-26 reduces biofilm biomass significantly at concentrations of 0.03-64 μg/mL over 24 hours, showing a biofilm clearance activity comparable to Voriconazole. Furthermore, during an incubation period of up to 25 hours, it inhibits the growth of Candida auris TDG1912 for at least 6 hours.

CYP51-IN-26 (Compound 7), administered locally at doses of 10-50 mg/kg 30 minutes post-infection, demonstrates significant antifungal activity in a greater wax moth (G. mellonella) model infected with Candida auris (TDG1912). Additionally, CYP51-IN-26, given at 5-50 mg/kg one hour post-infection, improves survival rates in a Drosophila melanogaster model infected with Candida auris.